It is World's Alzheimer's Day today. Professor Andrew Doig and Dr. Farid Khan discuss how clinical data and biomarker data can be combined using machine learning to diagnose early stages of Alzheimer's Disease. See the Guardian Article out today. Molecular and cellular changes to the brain are known to start decades [...]

It is World's Alzheimer's Day today. Professor Andrew Doig and Dr. Farid Khan discuss how clinical data and biomarker data can be combined using machine learning to diagnose early stages of Alzheimer's Disease. See the Guardian Article out today. Molecular and cellular changes to the brain are [...]

Manchester, UK, 3rd July 2023: PharmaKure, a company specialising in companion diagnostics for the treatment of neurological diseases and APIS Assay Technologies Ltd, a company with scientific expertise in biomarker translation, molecular diagnostics and bioinformatics have entered into a collaboration to progress a development project for the use of Clickmers [...]

1st July 2022. PharmaKure announce a ground breaking study of a blood biomarker trial using their proprietary ALZmetrix® assay with Alzheimer's disease patients.

March 26th 2021. PharmaKure is delighted to announce the completion of the acquisition of the CynapseDx assays for oligomeric proteins. This is the final step that secured invesment of £4 million from a private investor and the UK Future Fund to finance clinical trials on their leading drug candidate PK051 for Alzheimer's disease.

PharmaKure Limited and CynapseDx Limited have signed a letter of intent for a commercial relationship between the two companies which could result in a collaboration or acquisition to secure funding.